Comparative Pharmacokinetics of Rifaximin 550 mg and 200 mg Oral Tablets: One Is Not Like the Other

Zeev Heimanson, PharmD; Christopher Allen, MS; Brock Bumpass, PharmD, MBA, MS; Robert J. Israel, MD Salix Pharmaceuticals, Bridgewater, NJ

BACKGROUND

- Rifaximin (Xifaxan[®], Salix Pharmaceuticals) is available as 2 different formulations (200-mg and 550-mg oral tablets) and dosages are dependent on the condition being treated¹
 - Rifaximin 200 mg three times daily (TID; 600 mg/day) for 3 days is indicated for the treatment of travelers' diarrhea caused by noninvasive strains of *Escherichia coli* in patients aged ≥ 12 years
 - Rifaximin 550 mg TID (1650 mg/d) for 14 days is indicated for the treatment of irritable bowel syndrome with diarrhea in adults (patients who experience recurrence can be retreated for up to 2 times [same regimen]) - Rifaximin 550 mg two times daily (1100 mg/d) is indicated for reduction in risk of overt hepatic encephalopathy

 - recurrence in adults
- Given the availability of 2 rifaximin formulations (200 mg and 550 mg), questions have arisen regarding the interchangeability of tablets across various disease state dosing regimens

AIM


- To assess the pharmacokinetics (PK) and relative bioavailability of rifaximin 550-mg tablets and rifaximin 200-mg tablets (200, 400, and 600 mg)
- To determine whether rifaximin 200-mg tablets exhibit dose-proportional PK over a dose range of 200 to 600 mg

METHODS

- Phase 1, open-label, 5-treatment crossover PK study (Figure 1) in healthy volunteers aged 18 to 45 years with body mass index (BMI) between 18 and 32 kg/m²
- Study was approved by an institutional review board, and all individuals provided written informed consent • Participants were randomly assigned to a prespecified dosing sequence to receive the following treatments during the trial (Figure 1; 72-hour washout period between each treatment)
- Rifaximin 200 mg (one 200-mg tablet)
- Rifaximin 400 mg (two 200-mg tablets)
- Rifaximin 600 mg (three 200-mg tablets)
- Rifaximin 550 mg (one 550-mg tablet)
- Formulation not commercially available (data not included herein)

Figure 1. Study Design^{*}

۲



*A rifaximin formulation (not commercially available) was evaluated as an arm in the trial (ie, 5th treatment arm); data for this formulation are not reported herein. PK = pharmacokinetic.

- Plasma samples for PK analyses were collected prior to dosing and periodically through 12 hours postdose during each treatment period (Figure 1)
- Geometric mean ratios and 90% CI were calculated to determine dose proportionality - Doses were considered proportional if the 90% CI of the dose-normalized PK parameters after administration of rifaximin 400 mg (test) and rifaximin 600 mg (test) were within 80% to 125% (ie, lower and upper boundaries, respectively) compared with rifaximin 200 mg (reference)

- C_{max}, n
- T_{max}, h, AUC_{0-la}
- t_{1/2}, h,
- CL/F, L

Figure 2. Dose Proportionality Analysis

RESULTS

30 healthy volunteers were included in the trial

- 66.7% were male, the median age was 35.5 y (range, 20-45 y), 56.7% were black, and the median BMI was 28.1 kg/m² (range, 22.6-32.1 kg/m²)

• Rifaximin C_{max} following oral administration was relatively low across all 4 doses (Table) - Apparent oral clearance (CL/F) was relatively high due to the low oral bioavailability of rifaximin

Table. Pharmacokinetic Results (N=30)


Parameter	Rifaximin 200 mg	Rifaximin 400 mg	Rifaximin 600 mg	Rifaximin 550 mg
C _{max} , ng/mL, mean (SD)	0.94 (0.58)	1.83 (1.13)	2.50 (1.76)	0.91 (0.95)
T _{max} , h, median	1.43	0.93	0.97	0.87
AUC _{0-last,} h*ng/mL, mean (SD)	3.23 (1.55)	6.23 (3.04)	7.76 (4.69)	3.65 (3.66)
t _{1/2} , h, median	6.17*	5.29 [‡]	6.06¶	6.76**
CL/F, L/h, mean (SD)	45,700 (16,500)†	66,600 (45,100)§	76,000 (45,300)#	142,000 (89,900)**

*n=22. †n=20. ‡n=23. §n=21. ¶n=26. #n=25. **n=17.

AUC_{0-last} = concentration-time curve from time 0 to last measurement; CL/F = apparent oral clearance; C_{max} = maximum concentration; $t_{1/2}$ = terminal half-life; T_{max} = time to maximum observed serum concentration.

• For rifaximin 550 mg, both C_{max} , T_{max} , and AUC_{0-last} were lower than dosages using rifaximin 200-mg tablets $(C_{max} and T_{max} lower vs 200, 400, and 600 mg; AUC_{0-last} lower vs 400 and 600 mg) and CL/F was higher with$ rifaximin 550 mg (Table)

• Likewise, dose-normalized proportionality analyses indicated that the 200 mg, 400 mg, and 600 mg rifaximin dosages were not proportional based on 90% CI intervals (Figure 2)



AUC_{0-last} = concentration-time curve from time 0 to last measurement; C_{max} = maximum concentration; LSM = least-squares mean.

CONCLUSIONS

• PK data showed rifaximin was not dose proportional over the 200- to 600-mg range, suggesting that 200-mg tablet dosages are not interchangeable with the 550-mg tablet

• Increased exposure with intervals of 200-mg tablets may have implications for drug–drug interactions and potential for adverse drug reactions

- For example, in patients with hepatic impairment, who are already susceptible to increased rifaximin exposure¹ • Therefore, 200-mg rifaximin tablets should not be substituted for 550-mg rifaximin tablets

Reference: 1. Xifaxan[®] (rifaximin) tablets, for oral use [package insert]. Salix Pharmaceuticals; 2022.

Acknowledgements: The trial was supported by Salix Pharmaceuticals. Technical editorial and medical writing assistance were provided under direction of the authors by Mary Beth Moncrief, PhD, Synchrony Medical Communications, LLC, West Chester, PA. Funding for this assistance was provided by Salix Pharmaceuticals. **Disclosures:** All authors are employees of Salix Pharmaceuticals or its affiliates.





